Effect of N-Acetyl Cysteine in Rheumatoid arthritis
Phase 4
- Conditions
- Health Condition 1: M057- Rheumatoid arthritis with rheumatoid factor without organ or systems involvement
- Registration Number
- CTRI/2024/03/063534
- Lead Sponsor
- Government Kilpauk Medical College
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Newly diagnosed as rheumatoid arthritis within 2 years by ACR criteria and having DAS 28-ESR score more than 3.2 who are not responding to standard therapy
Exclusion Criteria
Newly diagnosed Rheumatoid arthritis patients having DAS 28-ESR score less than 3.2
History of Psychiatric illness or drug abuse
History of seizure disorder.
Known case of hypersensitive to N acetyl cysteine.
Pregnant and lactating females
History of any autoimmune disease other than rheumatoid arthritis
Patient taken biological agent therapy in last 6 months
Patients taking N acetyl cysteine for any other cause.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Disease activity assessed using DAS 28 ESR score and CRPTimepoint: at baseline and 12 weeks
- Secondary Outcome Measures
Name Time Method particpants will be assessed by CBC,LFT, RFT,CRP, ESR, RFTimepoint: at baseline , 4 ,8,12, 16 weeks